Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome

BACKGROUND: Rifaximin is a minimally absorbed antibiotic with high luminal activity, used to treat various gastrointestinal diseases. Although rifaximin has been proposed as first line treatment for small intestinal bacterial overgrowth (SIBO), few data are available regarding its efficacy in non-IB...

Descripción completa

Detalles Bibliográficos
Autores principales: Boltin, Doron, Perets, Tsachi Tsadok, Shporn, Einav, Aizic, Shoshana, Levy, Sigal, Niv, Yaron, Dickman, Ram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201689/
https://www.ncbi.nlm.nih.gov/pubmed/25319626
http://dx.doi.org/10.1186/s12941-014-0049-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201689/
https://www.ncbi.nlm.nih.gov/pubmed/25319626
http://dx.doi.org/10.1186/s12941-014-0049-x

Ejemplares similares